### Alert
This medication should only be administered by a medical officer or nurse practitioner.

### Indication
- **Respiratory distress syndrome (RDS).**
- **Meconium aspiration syndrome (MAS).**

### Action
Lowers surface tension on alveolar surfaces during respiration and stabilises the alveoli against collapse at resting trans pulmonary pressures.

### Drug Type
Pulmonary surfactant

### Trade Name
Curosurf

### Presentation
Suspension for intra-tracheal use 120 mg/1.5 mL or 240 mg/3 mL vials

### Dosage/Interval

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Loading dose</th>
<th>Repeat dose</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory distress syndrome</td>
<td>200 mg/kg</td>
<td>100 mg/kg every 6–12 hours</td>
<td>3 doses</td>
</tr>
<tr>
<td>Meconium aspiration syndrome</td>
<td>200 mg/kg</td>
<td>100 mg/kg</td>
<td>3 doses</td>
</tr>
</tbody>
</table>

Further doses can be given as below if required:
- 2nd dose: 200 mg/kg
- 3rd dose: 100 mg/kg
- 4th dose: 100 mg/kg

These doses can be administered at 6 hour interval.

### Maximum daily dose

### Total cumulative dose

### Route
Intra-tracheal

### Preparation/Dilution
Nil

### Administration

This medication should only be administered by a medical officer or nurse practitioner.

Inspect product visually for discolouration prior to administration (suspension should be white to creamy white). Before use, the vial should be slowly warmed to room temperature (can be warmed in hand or stood at room temperature) and gently turned upside down in order to obtain a uniform suspension. DO NOT SHAKE.

Poractant alpha is administered via the endotracheal route using an endotracheal tube (ETT) or thin catheter.

ETT administration: Assess patency and position of ETT prior to administration. Clear the trachea of secretions if required. Shorten a 5 French end-hole catheter so that the length of the catheter is 1 cm shorter than the ET tube. Slowly withdraw entire contents of vial(s) into a syringe through a needle (≥ 20 gauge). Do not shake. Attach shortened catheter to syringe. Fill catheter with surfactant. May administer in 1 to 2 aliquots as tolerated with the neonate in neutral supine position. If the infant is on a ventilator, the catheter can be inserted into the infant’s ET tube without interrupting ventilation by passing the catheter through a neonatal suction valve attached to the ET tube. This is especially useful in high-frequency ventilation to minimise de-recruitment. Alternatively, surfactant can be instilled through the catheter by briefly disconnecting the ETT from the ventilator. Approximately 2 mL of air may be used to push any remaining surfactant in the catheter into the lungs.
Thin catheter administration: Use a 4 French end-hole catheter marked approximately 1.5 cm above one end. Connect a syringe and catheter prefilled with surfactant preparation. While the infant is breathing via nasal CPAP, introduce laryngoscope and insert catheter using Magill forceps up to the mark on the catheter. Secure tube position and remove laryngoscope. With the infant’s mouth closed, instil surfactant during 30 to 120 seconds by mini-boluses. In cases of apnoea or bradycardia, perform positive pressure ventilation until recovery.

**Monitoring**
Continuous oxygen saturation and cardiorespiratory monitoring.

**Contraindications**
None known

**Precautions**
Correction of acidosis, hypotension, anaemia, hypoglycaemia and hypothermia is recommended by the manufacturer prior to poractant alpha administration but this is not always possible in practice.

**Drug Interactions**
N/A

**Adverse Reactions**
Transient: Bradycardia, hypotension, endotracheal tube blockage and oxygen desaturation. These events require stopping poractant alpha administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring. Ventilator settings may need to be adjusted post-surfactant to accommodate increased lung compliance.

**Compatibility**
Poractant alpha should not be mixed with any other medications or fluids.

**Incompatibility**
N/A

**Stability**
Vials are for single use only. DO NOT SHAKE. Unopened, unused vials that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. Document on the packaging the date and time the product was removed from the fridge. Notify Pharmacy Department/NICU Pharmacist if this occurs. Do not warm to room temperature and return to refrigerated storage more than once.

**Storage**
Store at 2−8°C. Protect from light.

**Special Comments**
Surfactant may alter amplitude-integrated electroencephalography (aEEG) recordings after administration.

---

**Original version Date:** 27/10/2015  
**Author:** Neonatal Medicines Formulary Consensus Group  
**Current Version number:** 1  
**Current Version Date:** 27/10/2015  
**Risk Rating:** Medium  
**Due for Review:** 27/09/2019  
**Approval by:** JHCHCQ&PCC  
**Approval Date:** 27/09/2016